Mr. Naaman is an Associate Director in the Genentech’s Pipeline and Portfolio Planning group, where he is of responsible for the Immunology, Ophthalmology and Infectious Diseases portfolios. In his role, Mr. Naaman advises therapeutic area leaders and Genentech’s late stage portfolio committee on portfolio topics, including program valuation, portfolio mix and prioritization, and development strategy. Before joining Genentech, Mr. Naaman was an Associate Partner in Oliver Wyman’s Health and Life Sciences practice. At Oliver Wyman, Charles was a member of the life sciences leadership team and oversaw the largest client account for the practice. Mr. Naaman received a B.S.ME from the University of Michigan and holds an M.B.A. and Masters of Engineering Management from the Kellogg School of Management at Northwestern University.